Back to discover

Protein / target

Dihydropteroate synthase

folP1P0C0X1Mycobacterium leprae (strain TN)Swiss-Prot
23
Clinical trials
1
Drugs targeting

Protein at a glance

Biological role

Dihydropteroate synthase

Derived from structured UniProt, Open Targets and literature data on this page.

Protein profile

UniProt 2026_02

Canonical identity and biological annotation from UniProt.

Function overview

Catalyzes the condensation of para-aminobenzoate (pABA) with 6-hydroxymethyl-7,8-dihydropterin diphosphate (DHPt-PP) to form 7,8-dihydropteroate, the immediate precursor of folate derivatives

Domains and Gene Ontology detail (6)

Domains & features

Pterin-binding

Gene Ontology

  • Ccytosol
  • Fdihydropteroate synthase activity
  • Fmetal ion binding
  • Pfolic acid biosynthetic process
  • Ptetrahydrofolate biosynthetic process

284 aa · 29 kDa

Approved medicines with mapped indications

1 medicine · 3 areas

Approved therapies targeting this protein, grouped by what they are approved to treat — the disease-first view of the medicines below. Relationships come from the canonical approved-indication graph (ChEMBL phase-4), the same source as the drug cards.

Acne Vulgaris1 medicine
Dermatitis Herpetiformis1 medicine
Leprosy1 medicine

Approved indications from ChEMBL (phase-4), via the canonical drug→disease graph.

Drugs targeting this protein

1

How approved and investigational drugs engage this protein — mechanism and action type, direct vs complex targeting, and how broadly each acts across other targets. A drug-first view (the section above groups the approved ones disease-first); direct binders with few recorded targets are listed first.

Dapsone
Narrow target profileInhibitor

Dihydropteroate synthase 1 inhibitor

Indicated for Acne Vulgaris, Dermatitis Herpetiformis, Leprosy

Direct interaction with this protein · Only this protein recorded as a target

ChEMBL mechanism, action type, target identity and approved indications. Open Targets clinical status.

Clinical trials

23

Trials of drugs that target this protein — reached indirectly through those drugs, so a trial listed here studies the drug, not the protein. Ranked by active status, then clinical phase and recency, and spread across the targeting drugs.

View all trials (19)

COMPLETED · via Dapsone · NCT00000596

UNKNOWN · via Dapsone · NCT04918914

ClinicalTrials.gov via the drug-target graph.

What's happening now

4

Recent therapeutic activity around this target — regulatory actions, clinical trials and safety signals for a drug that targets this protein, plus publications where such a drug is a genuine subject. Every item is reached indirectly through the drug, not the protein itself; incidental mentions (a paper that merely measures a drug) and press items are excluded.

  1. Regulatory approval2026-07-08

    Approval: DAPSONE (ANDA218335)

    fda · regulatory · fda · via Dapsone

  2. Regulatory approval2026-06-25

    Approval: DAPSONE (ANDA213414)

    fda · regulatory · fda · via Dapsone

  3. Product recall2024-10-29

    Recall (Class II): DAPSONE

    fda · safety · fda · via Dapsone

  4. New publication2019-06-11
    Dermatitis Herpetiformis: Novel Perspectives.

    Frontiers in immunology · 2019 · 51 citations · Europe PMC · via Dapsone

Objective event titles are shown unmodified; the event kind and significance line are derived from structured fields. Forefront AttentionEvent stream aggregating Europe PMC Regulatory filings ClinicalTrials.gov.